Las Zanjillas (Torrejón de Velasco, Madrid) es un yacimiento Calcolítico precampaniforme ubicado en el valle medio del Tajo, caracterizado por más de 500 estructuras que incluyen silos y cubetas. Este estudio se centra en el análisis zooarqueológico y tafonómico de muestras óseas encontradas en este sitio. A diferencia de otras acumulaciones faunísticas en sitios precampaniformes de la región, aquí no se observan depósitos de individuos completos de animales; en cambio, se identifican acumulaciones de fauna de contextos domésticos, mayormente compuestas por restos de vacas y caprinos. Los análisis tafonómicos revelan la presencia de marcas de cortes en todos los taxones, indicando un aprovechamiento cárnico de los animales. No obstante, los patrones de mortalidad identificados en las distintas especies domésticas señalan un predominio de individuos adultos, lo que podría sugerir usos alternativos de las cabañas ganaderas más allá de su función exclusivamente cárnica. Este aspecto, sumado a las cronologías proporcionadas por el sitio, plantea un interesante punto de discusión que abordaremos en este trabajo.
Regarding the wide genetic and antigenic variability of influenza viruses, overall or subtype influenza vaccine effectiveness (IVE) estimates may not be sufficient to assess vaccine protection against circulating strains. This is particularly important when low VE against a specific clade is suspicious or a new drifted virus is emerging. Viral genetic characterization is routinely performed in influenza surveillance but viruses are selected according patient age, severity and vaccine status. For instance, last season genetic characterized cases were more vaccinated than those not selected. A protocol for virological data integration on IVE studies within I-MOVE network was performed. It intended to solve the following issues: 1. Selection of the clade of interest to provide IVE; 2. Determination of the number of cases needed for genetic characterization; 3. Selection of cases for genetic characterization independently of patient features. During the 2015/16 season, a closely contact between epidemiological and laboratorial teams allows to perform a random selection of influenza cases for genetic characterization independently of cases features. Influenza A(H1N1)pdm09 was the selected subtype given its predominance and the emergence of new subclades (6B.1 and 6B.2). 52.2% of A(H1)pdm09 cases were successfully characterized. No differences regarding age, sex and vaccine status were found between selected and unselected cases for genetic characterization. The large sample size needed to estimate IVE against a specific clade requires an important effort on genetic characterization behind virological surveillance. However, random selection of cases for genetic characterization along season seems to be feasible without interfering with virological surveillance and obtains a representative sample of cases of the clade of interest. Virological data from randomly selected cases will permit to estimate IVE against a specific clade during influenza season. An extra effort on influenza genetic characterization is needed to achieve the needed sample size. ; This project was financed by the European Center for Disease Prevention and Control for data and actvi;es related to the individuals with less then 65 years. Data and activities related to the individuals 65 years and more were funded by European Union's Horizon 2020 research and innova;on programme under grant agreement No 634446. ; N/A
EVA Hospital Group: Irina Kislaya, Ana Paula Rodrigues, Liliana Dias, Paula Branquinho, Cláudia Mihon, Ana Rita Estriga, Ana Brito, Luís Vale, Helena Pacheco, André Almeida, Helena Amorim, Paula Lopes, Vitor Augusto, Rosa Ribeiro, Regina Viseu, Raquel Guiomar, Pedro Pechirra, Paula Cristovão, Patrícia Conde. ; Erratum in: Acta Med Port. 2021 Jan 4;34(1):70-73. doi:10.20344/amp.15515. Epub 2021 Jan 4. ; Introduction: The project 'Integrated Monitoring of Vaccines in Europe' aimed to measure seasonal influenza vaccine effectiveness against hospitalised adults, aged 65 years and over, with influenza. We describe the protocol implementation in Portugal. Material and Methods: We implemented a test-negative design, targeting community-dwelling patients aged 65 years old and over hospitalised with severe acute respiratory illness. Patients were reverse transverse-polymerase chain reaction tested for influenza. Cases were those positive for influenza while others were controls. Most variables were collected using hospital medical records. Selection bias was evaluated by comparison with the laboratory influenza test requests database according to demographic characteristics. Crude, season-adjusted influenza vaccine effectiveness was estimated as = 1 – odds ratio, and 95% confidence intervals were obtained by conditional logistical regression, matched with the disease onset month. Results: The recruitment rate was 37.8%. Most participants (n = 368) were female (55.8%) and aged 80 years old and over (55.8%). This was similar to values for potentially eligible severe acute respiratory illness patients (80 years old and over: 56.8%, female: 56.2%). The proportion of missing values was below 2.5% for 20 variables and above 5% (maximum 11.6%) for six variables. Influenza vaccine effectiveness estimates were 62.1% against AH1pdm09 (95% confidence intervals: -28.1 to 88.8), 14.9% against A(H3N2) (95% confidence intervals: -69.6 to 57.3), 43.6% against B/Yam (95% confidence intervals: -66.2 to 80.8). Discussion: Given the non-existence of a coded admission database in either participating hospital the selection of severe acute respiratory illness due to clinical features was the feasible one. These results are only valid for the older adult population residing in the catchment area of the two participating hospitals who were admitted to a public hospital with severe influenza or SARI symptoms. Conclusion: Despite the low participation rate, we observed comparable characteristics of participants and eligible severe acute respiratory illness patients. Data quality was high, and influenza vaccine effectiveness results were in accordance with the results of meta-analyses and European season-specific estimates. The final sample size was low, which inhibited obtaining estimates with good precision. ; Introdução: O projeto "Integrated Monitoring of Vaccines in Europe" pretende medir a efetividade da vacina antigripal nas hospitalizações por gripe nos adultos com mais de 65 anos. Este estudo pretende descrever a implementação do protocolo em Portugal. Material e Métodos: Implementou-se um estudo com desenho caso-controlo teste negativo. A população-alvo foram indivíduos com idade superior a 65 anos, hospitalizados com doença respiratória aguda grave. Os doentes foram testados para gripe por reverse transverse-polimerase chain reaction. Foram considerados casos aqueles com resultado positivo; os restantes foram controlos. Os dados foram obtidos através de registo clinicos. O potencial viés de seleção foi avaliado por comparação de características demográficas e enfermarias com dados das requisições laboratoriais. A efetividade da vacina, foi estimada em 1 – odds ratio por regressão logística condicional, emparelhada para o mês de início da doença. Resultados: A taxa de recrutamento foi de 37,8%. A maioria dos participantes (n = 368) era do sexo feminino (55,8%) e tinha idade superior a 80 anos (55,8%). Padrão similar foi verificado nos doentes elegíveis (idade superior a 80 anos: 56,8%; feminino: 56,2%). Os valores omissos foram inferiores a 2,5% em 20 variáveis e acima de 5% (máximo 11,6%) em seis variáveis. As estimativas da efetividade foram 62,1% contra AH1pdm09 (intervalo de confiança IC 95%: -28,1, 88,8); 14,9% contra A (H3) (intervalo de confiança 95%: -69,6; 57,3) e 43,6% contra B/yamagata (intervalo de confiança 95%: -66,2; 80,8). ; Abstract in English, Portuguese ; This work is part of I-MOVE+ (Integrated Monitoring of Vaccines in Europe) project that received funding from the European Union's Horizon 2020 research and innovation programme [grant agreement number 634446]. ; info:eu-repo/semantics/publishedVersion
As the COVID-19 pandemic began in early 2020, primary care influenza sentinel surveillance networks within the Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE) consortium rapidly adapted to COVID-19 surveillance. This study maps system adaptations and lessons learned about aligning influenza and COVID-19 surveillance following ECDC / WHO/Europe recommendations and preparing for other diseases possibly emerging in the future. Using a qualitative approach, we describe the adaptations of seven sentinel sites in five European Union countries and the United Kingdom during the first pandemic phase (March–September 2020). Adaptations to sentinel systems were substantial (2/7 sites), moderate (2/7) or minor (3/7 sites). Most adaptations encompassed patient referral and sample collection pathways, laboratory testing and data collection. Strengths included established networks of primary care providers, highly qualified testing laboratories and stakeholder commitments. One challenge was the decreasing number of samples due to altered patient pathways. Lessons learned included flexibility establishing new routines and new laboratory testing. To enable simultaneous sentinel surveillance of influenza and COVID-19, experiences of the sentinel sites and testing infrastructure should be considered. The contradicting aims of rapid case finding and contact tracing, which are needed for control during a pandemic and regular surveillance, should be carefully balanced.
I-MOVE-COVID-19 primary care study team (in addition to authors above): Nick Andrews, Jamie Lopez Bernal, Heather Whitaker, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Verónica Gomez, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Ana Martínez Mateo, Luca Basile, Daniel Castrillejo, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva. ; The I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination. ; This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673. ; info:eu-repo/semantics/publishedVersion
